Sucampo Pharmaceuticals — Corporate Update (January 2016)
26 slides from Sucampo Pharmaceuticals's corporate update, Jan 11, 2016
Slide 1: Sucampo Pharmaceuticals, Inc. Corporate Update
$ SUCAMPO ‘The Science of Innovation Sucampo Pharmaceuticals, Inc. Corporate Update January 11-13, 2016 Peter Greenleaf, Chief Executive Officer Peter Kiener, Chief Scientific Officer Andrew Smith, Chief Financial Officer Silvia Taylor, Senior Vice President, Investor Relations and Corporate Affairs
Slide 2: Forward Looking Statements
Forward Looking Statements $ sucampo This presentation contains “forward-looking statements’ as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results t
Slide 3: Investment Highlights
Investment Highlights + Fast-growing global biopharmaceutical company with increasing revenues and focus on innovative R&D of proprietary drugs * Sustained revenue growth from AMITIZA® (lubiprostone): highly differentiated product with broadest label in $5B+ constipation market + Diversified pipelin
Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company
Clear Strategy to Methodically Build a Leading Bio/Pharma Company $ sucampo_ + Focus efforts and strengthen overall capabllities - Team = Development capability * Secure and grow AMITIZA revenues = Efforts to ensure consistent and sustainable growth = Global partnerships = Resolution of patent litig
Slide 5: AMITIZA: Constipation Market Overview
AMITIZA: Constipation Market Overview Significant unmet need in efficacy, safety and patient satisfaction + U.S. prescription and OTC market ~$5.2B, growing 6%+ annually (2015) — $4.4B branded + generic market, ~50M annual scripts (1) = Additional $800M in revenue from OTC market, 23M units (30-day
Slide 6: Prescription Constipation Market Is Large and Growing
Prescription Constipation Market Is Large and Growing $ sucampo_ Share of Prescription Chronic Infrequent and difficult passage of stool Idiopathic over 12 non-consecutive weeks within a Constipation 12-month period (cic) ~14% to 16% of adults globally enede Disorder of the intestines; symptoms are
Slide 7: AMITIZA: Broadest Label in Constipation Market
AMITIZA: Broadest Label in Constipation Market + Only product approved for all 3 indications - cic - IBS-C = OIC (non-cancer) + Differentiated MOA: localized CIC-2 activation with dual action — Increases intestinal fluid secretion — Stimulates recovery of mucosal barrier function + Key product chara
Slide 8: AMITIZA Prescription Growth is Accelerating
AMITIZA Prescription Growth is Accelerating $ sucampo November Rx YOY growth rates: TRx 10%; NRx 14% U.S. TRx Scripts Japan TRx Scripts” ooo Anuaaed ‘asa (rneusnae (rosso) Z 1,585 ast | is tne joo tte 1.132 1.105, 1231 1264 a0 3 8 Se ar Si ane” aS a er oie 18 ao UTM aaMne U.S. Net Price per Day Japa
Slide 9: Blue-Chip Partnerships Provide Global Reach for AMITIZA
Blue-Chip Partnerships Provide Global Reach for AMITIZA $ sucampo_ + Takeda markets AMITIZA in U.S., Canada, U.K. and Switzerland; 800 sales reps in U.S. — Takeda is #1 gastroenterology company world wide and has rights to all markets except Japan Key Partnerships (Mylan) and China = Royalty arrange
Slide 10: Competitive Overview
Competitive Overview $ sucampo Branded / Patented Generic AMITIZA is well positioned for continued growth Target Company Vamitiza x 1 lubiprostone Linzess* — , \onwood insblpeees (Marketedby Actavis) Sucampo (Marketed by Takeda) ication x x of Commentary Long history ofusage Welrtolerated product wi
Slide 11: AMITIZA Lifecycle Management
AMITIZA Lifecycle Management $ sucampo_ Expand AMITIZA franchise through new formulation and new indication New Formulation + Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso- gastric tube fed patients + ~40% of adults have difficulty swallowing
Slide 12: AMITIZA Growth Strategy
AMITIZA Growth Strategy $ sucampo_ Y Underpenetrated markets with Expanded Takeda agreement Targeting ing 30% of brand sales EXPANDED PARTNERSHIP URIN ¥ Yearly Increases Y RTU Acquisition increases AMITIZA tevenue v Takeda + Net sales revenue split on brand lubiprostone, incl. LOM v Agreement with P
Slide 13: The Recent Addition of R-Tech Ueno Provides Significant Benefit
The Recent Addition of R-Tech Ueno Provides Significant @ sucampo Benefit ee ieee Global pharmaceutical company focused on the research and development of drugs in Company gastroenterology, ophthalmology and dermatology Peseription Exclusive manufacturer and supplier of AMITIZA and RESCULA (unoprost
Slide 14: Strengthened Financial Position of Combined Company
Strengthened Financial Position of Combined Company $ SUCAMPO_ ‘Sucampo RTU Key Products Gastroenterology, Ophthalmology __ Gastroenterology, Ophthalmology 2 2 $133.6M $63.7M ssa. 156M oe uae Revenue by Partner Combined Gastroenterology, Ophthalmology 2 $175.4M (0 $86.1M®) Reseda oe AMA 38 tte oh
Slide 15: Product Pipeline Overview
Product Pipeline Overview Created, Far Ackoomaave Pabst Ps RTUs096 Nast PD Exclisive option ftom CPP (ral emulation ‘Ophthalmology urn Retnts Piomeniosa RUAOL Severe dy 230 Pa Sustonce RUA05 P PostLasikeored epthetl defects Pip S164 4 DabatieRetnopaty Rrso%s Vitr — Ganalcmacuar edema ce rat 22 ‘Age-
Slide 16: CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP
CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP $ sucai + Significant opportunity = Orphan indication in U.S. for familial adenomatous polyposis (FAP) + 30K cases — No approved treatment options — Dire patient need + 100% risk of colon cancer + Progressive removal of colon/rectum +
Slide 17: Cobiprostone: Phase 2 Asset in NERD/sGERD
Cobiprostone: Phase 2 Asset in NERD/SGERD + Significant opportunity — 2-42% of total population is Proton-Pump Inhibitor (PPI) refractory Nonerosive Reflex Disease (NERD)/ Symptomatic Gastroesophageal Reflux Disease (sGERD) — No effective treatment options available for patients refractory to PPIs ‘
Slide 18: R-Tech Ueno Pipeline
R-Tech Ueno Pipeline $ sucampo_ VAP-1 inhibitors — VAP-1 is an enzyme and adhesion receptor — Potential indications including NASH, COPD, diabetic macular edema and diabetic retinopathy and modulation of tumor-specific immune responses + RTU-1096 — MAD Phase 1b — Next step: generate additional precl
Slide 19: Strong Financial Performance
Strong Financial Performance $ sucampo_ Sucampo’s Strong Revenue Growth: Q3 Sucampo is Profitable and Cash Generating: Q3 + Total revenues up 6% to $33.4M + Net income = $7.2M * Product royalty revenue up 15% to $19.3M + EPS=$0.16 + Product sales revenue up 20% to $11.0M (excl. 2014 + Operating cash
Slide 20: Upcoming Milestones
Upcoming Milestones SUCAMPO_ Cobiprostone AMITIZA (lubiprostone) AMITIZA (ubiprostone) AMITIZA (ubiprostone) AMITIZA (ubiprostone) AMITIZA (lubiprostone) Cobiprostone AMITIZA (lubiprostone) Top-line data from Phase 2 NERD/sGERD Initiation of Phase 3 pivotal alternate formulation in adults Top-line d
Slide 21: Investment Highlights
Investment Highlights + Fast-growing global biopharmaceutical company with increasing revenues and focus on innovative R&D of proprietary drugs * Sustained revenue growth from AMITIZA® (lubiprostone): highly differentiated product with broadest label in $5B+ constipation market + Diversified pipelin
Slide 22: Back Up Slides
Back Up Slides
Slide 23: Patent Overview
Patent Overview $ sucampo_ AMITIZA well-protected by a comprehensive suite of patents through 2027 U.S. '067, 174, ‘649, US. '934 "890, '542, ‘393, 187, Patent expires 2021 ‘639 Latest patent expires 2027 U.S. 182, '748, '969, U.S. ‘016, ‘613, '283, "562, 064 "148, "653, 481, 312 Latest patent expir
Slide 24: Cobiprostone: Oral Mucositis
Cobiprostone: Oral Mucositis + Significant opportunity I ~60K U.S. patients develop HNC annually More than half treated with radiation ~550K HNC cases annually worldwide Limited treatment options for OM with no approved therapies in the U.S. Incremental opportunity of $50-$100M in the U.S. + Differe
Slide 25: Proven and Experienced Management Team
Proven and Experienced Management Team $ sucampo_ Experienced management team with considerable experience in product development and commercialization Peter Greenleat Cites li folmenfehen © centocor Peter Kiener, D.Phil Bristol Myers Squibb lil Ambrx Zyngenia _ Matthias Alder CYTOS micr@met Ub Nova
Slide 26: Sucampo Evolution
Sucampo Evolution 9 1989 9 1994 9996 Tech Ueno, Lid RESCULA — ‘Dr. Sachiko Kune and Or. Ueno established Jaunchedin {found RTU Ueno (USAY, inc, later to Japan lbecome Sueampo $2006 42007 42008 © $2009 $2010» 42012 $2013 42015 ‘AMITIZA. nal Public AMITIZA — AMITIZA —-Sucampo—AMITIZA ‘AMITIZA ‘Austia,
Sucampo Pharmaceuticals — Corporate Update (January 2016) on 6ix